• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search
Home » Clinical Trials

Clinical Trials

Rebiotix Inc., a Ferring Company, is working closely with the U.S. FDA as it conducts an advanced clinical research program

Clinical Trials

Rebiotix Inc., a Ferring Company, has conducted several clinical trials with it’s lead microbiota-based product in the MRT™ drug platform, RBX2660 for the prevention of recurrent Clostridioides difficile (C. diff) infection. The trials were conducted under the U.S Food and Drug Administration’s Investigational New Drug (IND) Application, as well as HealthCanada’s Clinical Trial Application (CTA) regulations.

For currently enrolling clinical trials, go to clinicaltrials.gov.

Important milestones include:

  • PUNCH CD study: Phase 2 multicenter, open-label study.
  • PUNCH CD 2: Phase 2B, prospective, multi-center randomized double-blind, placebo-controlled study of a microbiota-based drug.
  • PUNCH Open Label: Phase 2 prospective, multi-center, open label controlled trial.
  • Phase 3 PUNCH CD 3 – completes enrollment (click for details).
  • Acquired by Ferring Pharmaceuticals in April 2018.
  • Rebiotix Announces World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660.

Special FDA designations for RBX2660:

  • Fast Track – May 2013
  • Orphan Drug – March 2014
  • Breakthrough Therapy – October 2015

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us